XL092 and cemiplimab for advanced thyroid cancer without BRAF mutation
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with anaplastic thyroid cancer (a rare and fast-growing form of thyroid cancer).
- Your tumor does not have the BRAF V600E mutation.
- You are at least 18 years old and able to have a fresh biopsy if no old tumor sample is available.
- You have not had any prior immune-modulating or kinase inhibitor drugs that stopped working for you.
- You do not have an active autoimmune condition that requires strong immune-suppressing medications.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, zanzalintinib and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer that has not spread to the brain or been treated with similar drugs. The study aims to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
This trial is testing a new oral medication, XL092, for people with advanced thyroid cancer that has stopped responding to radioactive iodine therapy. The goal is to see if XL092 can slow or stop the cancer from growing.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.